MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-10-2023
Syneos Health Retained Earnings 2011-2025 | SYNH
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -13 M | - | -341 M | -459 M | -370 M | -230 M | -301 M | -217 M | -189 M | -147 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -13 M | -459 M | -252 M |
Quarterly Retained Earnings Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 95.5 M | 168 M | - | - | -52.6 M | -13 M | -88.9 M | -167 M | -166 M | -180 M | -180 M | -180 M | -180 M | -341 M | -341 M | -341 M | -341 M | -459 M | -459 M | -459 M | -459 M | -370 M | -370 M | -370 M | -370 M | -230 M | -230 M | -230 M | -230 M | -301 M | -301 M | -301 M | -301 M | -217 M | -217 M | -217 M | -217 M | -189 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 168 M | -459 M | -245 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-77.3 M | $ 19.06 | -1.6 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 20.31 | -5.8 % | $ 221 M |  China |
 |
Co-Diagnostics
CODX
|
4.6 M | $ 0.23 | -4.17 % | $ 6.75 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 39.2 | -0.49 % | $ 1.09 B | USA |
 |
Danaher Corporation
DHR
|
44.2 B | $ 230.87 | 0.23 % | $ 169 B | USA |
 |
DarioHealth Corp.
DRIO
|
-349 M | $ 10.36 | 3.19 % | $ 294 M | Israel |
 |
BioNano Genomics
BNGO
|
-693 M | $ 1.51 | -0.9 % | $ 1.92 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Exact Sciences Corporation
EXAS
|
-4.5 B | $ 101.86 | 0.28 % | $ 18.9 B | USA |
 |
DexCom
DXCM
|
1.02 B | $ 67.65 | 0.12 % | $ 26.1 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 26.63 | -0.34 % | $ 805 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
-678 M | $ 19.19 | -1.49 % | $ 1.03 B | USA |
 |
Celcuity
CELC
|
-272 M | $ 101.0 | -1.22 % | $ 3.98 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
Anixa Biosciences
ANIX
|
-241 M | $ 3.19 | -0.31 % | $ 102 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
6.06 B | $ 227.26 | 0.15 % | $ 41.2 B | USA |
 |
Guardant Health
GH
|
-2.58 B | $ 100.93 | -1.99 % | $ 12.4 B | USA |
 |
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
-757 M | $ 6.32 | -2.55 % | $ 573 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-103 M | $ 4.75 | -4.81 % | $ 2.55 M | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 7.2 | 0.98 % | $ 1.56 B | USA |
 |
National Research Corporation
NRC
|
-30.5 M | $ 18.95 | 1.55 % | $ 465 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 134.56 | -0.29 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
1.81 B | $ 203.33 | -0.11 % | $ 10.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.36 B | $ 175.36 | -0.34 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
-462 M | $ 6.79 | -0.44 % | $ 880 M | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
8.3 B | $ 252.95 | -0.4 % | $ 21.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 182.75 | -0.05 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
5.33 B | $ 685.99 | -0.36 % | $ 56.6 B | USA |
 |
Lantheus Holdings
LNTH
|
446 M | $ 67.0 | 0.43 % | $ 4.64 B | USA |
 |
Personalis
PSNL
|
-550 M | $ 8.01 | -1.6 % | $ 475 M | USA |
 |
Mettler-Toledo International
MTD
|
8.37 B | $ 1 419.41 | -0.06 % | $ 30.1 B |  Schweiz |
 |
Agilent Technologies
A
|
348 M | $ 138.09 | -0.22 % | $ 42 B | USA |
 |
Quidel Corporation
QDEL
|
945 M | $ 29.27 | -0.12 % | $ 1.23 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.6 | -3.7 % | $ 5.97 M | USA |